Olprinone hydrochloride (BioDeep_00000658662)

   


代谢物信息卡片


Olprinone (Hydrochloride)

化学式: C14H11ClN4O (286.0621346)
中文名称: Olprinone Hydrochloride
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1=C(C=C(C(=O)N1)C#N)C2=CN3C=CN=C3C=C2.Cl
InChI: 1H

描述信息

D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors > D058987 - Phosphodiesterase 3 Inhibitors
D020011 - Protective Agents > D002316 - Cardiotonic Agents
D002317 - Cardiovascular Agents

同义名列表

2 个代谢物同义名

Olprinone (Hydrochloride); Olprinone hydrochloride



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Shintaro Dobashi, Ippei Watanabe, Rine Nakanishi, Shinji Hisatake, Shunsuke Kiuchi, Takayuki Kabuki, Takashi Oka, Takahiro Fujii, Takanori Ikeda. Comparing the effects of milrinone and olprinone in patients with congestive heart failure. Heart and vessels. 2020 Jun; 35(6):776-785. doi: 10.1007/s00380-019-01543-6. [PMID: 31865433]
  • Martin Kertys, Petra Kosutova, Daniela Mokra, Juraj Mokry. Development of rapid and high-throughput LC-MS/MS method for quantification of olprinone in rabbit plasma. Biomedical chromatography : BMC. 2019 Oct; 33(10):e4620. doi: 10.1002/bmc.4620. [PMID: 31215048]
  • Mohamed Bejaoui, Mohamed Amine Zaouali, Rim Sakly, Hassen Ben Abdennebi. Olprinone protects the liver from ischemia-reperfusion injury through oxidative stress prevention and protein kinase Akt activation. Canadian journal of physiology and pharmacology. 2018 Mar; 96(3):227-231. doi: 10.1139/cjpp-2017-0153. [PMID: 28675791]
  • Paul Gavra, Anne Q-N Nguyen, Yves Theoret, Catherine Litalien, André Y Denault, France Varin. A specific and sensitive HPLC-MS/MS micromethod for milrinone plasma levels determination after inhalation in cardiac patients. Therapeutic drug monitoring. 2014 Oct; 36(5):663-8. doi: 10.1097/ftd.0000000000000072. [PMID: 24690585]
  • Kohta Iguchi, Etsuro Hatano, Kenya Yamanaka, Motohiko Sato, Gen Yamamoto, Yosuke Kasai, Tatsuya Okamoto, Masayuki Okuno, Kojiro Taura, Kyoko Fukumoto, Kazuyuki Ueno, Shinji Uemoto. Hepatoprotective effect by pretreatment with olprinone in a swine partial hepatectomy model. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2014 Jul; 20(7):838-49. doi: 10.1002/lt.23884. [PMID: 24700629]
  • Hongbo Wang, Baochang Zhang, Xilin Sun, Yantong Sun, Meiyun Shi. Method development and validation of olprinone in human plasma by HPLC coupled with ESI-MS-MS: application to a pharmacokinetic study. Journal of chromatographic science. 2014 May; 52(5):400-5. doi: 10.1093/chromsci/bmt049. [PMID: 23690065]
  • D Mokra, I Tonhajzerova, H Pistekova, Z Visnovcova, J Mokry, A Drgova, M Repcakova, A Calkovska. Short-term cardiovascular effects of selective phosphodiesterase 3 inhibitor olprinone versus non-selective phosphodiesterase inhibitor aminophylline in a meconium-induced acute lung injury. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2013 Dec; 64(6):751-9. doi: NULL. [PMID: 24388890]
  • D Mokra, A Drgova, J Kopincova, R Pullmann, A Calkovska. Anti-inflammatory treatment in dysfunction of pulmonary surfactant in meconium-induced acute lung injury. Advances in experimental medicine and biology. 2013; 756(?):189-96. doi: 10.1007/978-94-007-4549-0_24. [PMID: 22836635]
  • Daniela Mokra, Anna Drgova, Rudolf Pullmann, Andrea Calkovska. Selective phosphodiesterase 3 inhibitor olprinone attenuates meconium-induced oxidative lung injury. Pulmonary pharmacology & therapeutics. 2012 Jun; 25(3):216-22. doi: 10.1016/j.pupt.2012.02.007. [PMID: 22387424]
  • Katsushi Kinouchi, Kiyozo Morita, Yoshihiro Ko, Ryuichi Nagahori, Gen Shinohara, Takayuki Abe, Kazuhiro Hashimoto. Reversal of oxidant-mediated biochemical injury and prompt functional recovery after prolonged single-dose crystalloid cardioplegic arrest in the infantile piglet heart by terminal warm-blood cardioplegia supplemented with phosphodiesterase III inhibitor. General thoracic and cardiovascular surgery. 2012 Feb; 60(2):73-81. doi: 10.1007/s11748-011-0810-4. [PMID: 22327851]
  • Emanuela Mazzon, Emanuela Esposito, Rosanna Di Paola, Daniela Impellizzeri, Placido Bramanti, Salvatore Cuzzocrea. Olprinone, a specific phosphodiesterase (PDE)-III inhibitor, reduces the development of multiple organ dysfunction syndrome in mice. Pharmacological research. 2011 Jul; 64(1):68-79. doi: 10.1016/j.phrs.2010.12.010. [PMID: 21193041]
  • Ping Zhu, Yu-Guan Wen, Ji-Mei Chen, Jian Zhuang, Zhi-Ling Zhou, Shao-Yi Zheng, Ruo-Bin Wu, Xue-Jun Xiao, Cong Lu, Rui-Xin Fan, Hui-Ming Guo, Xiao-Ping Fan. Determination of olprinone in human plasma utilizing liquid chromatography tandem mass spectrometry. Journal of pharmaceutical and biomedical analysis. 2011 Jan; 54(1):198-202. doi: 10.1016/j.jpba.2010.07.016. [PMID: 20728297]
  • Terumoto Koike, Muhammad Nadeen Qutab, Masanori Tsuchida, Masaru Takekubo, Masayuki Saito, Jun-ichi Hayashi. Pretreatment with olprinone hydrochloride, a phosphodiesterase III inhibitor, attenuates lipopolysaccharide-induced lung injury via an anti-inflammatory effect. Pulmonary pharmacology & therapeutics. 2008; 21(1):166-71. doi: 10.1016/j.pupt.2007.01.007. [PMID: 17434327]
  • Chabouk Anas, Takenori Ozaki, Shoichi Maruyama, Tokunori Yamamoto, Momoka Zu Gotoh, Yoshinari Ono, Seiichi Matsuo. Effects of olprinone, a phosphodiesterase III inhibitor, on ischemic acute renal failure. International journal of urology : official journal of the Japanese Urological Association. 2007 Mar; 14(3):219-25. doi: 10.1111/j.1442-2042.2007.01689.x. [PMID: 17430259]
  • Y Zhang, Q Ma. The enhancement of cellular cAMP with olprinone protects autotransplanted rat kidney against cold ischemia-reperfusion injury. Transplantation proceedings. 2006 Jun; 38(5):1580-3. doi: 10.1016/j.transproceed.2006.02.065. [PMID: 16797361]
  • Masanori Onomoto, Isao Tsuneyoshi, Arata Yonetani, Shoich Suehiro, Kazuhisa Matsumoto, Ryuzo Sakata, Yuichi Kanmura. Differential pharmacologic sensitivities of phosphodiesterase-3 inhibitors among human isolated gastroepiploic, internal mammary, and radial arteries. Anesthesia and analgesia. 2005 Oct; 101(4):950-956. doi: 10.1213/01.ane.0000172114.30383.23. [PMID: 16192501]
  • Akio Mizutani, Kazunori Murakami, Kenji Okajima, Shin-Ichiro Kira, Sachiko Mizutani, Kyosuke Kudo, Junji Takatani, Koji Goto, Seiji Hattori, Takayuki Noguchi. Olprinone reduces ischemia/reperfusion-induced acute renal injury in rats through enhancement of cAMP. Shock (Augusta, Ga.). 2005 Sep; 24(3):281-7. doi: 10.1097/01.shk.0000175555.95676.34. [PMID: 16135969]
  • Masanobu Mori, Shinichi Nishi, Akira Asada. Pharmacokinetics and pharmacodynamics of olprinone after cardiac surgery. Osaka city medical journal. 2004 Jun; 50(1):1-8. doi: NULL. [PMID: 15646253]
  • Miyuki Itou, Hirotsugu Okamoto, Junko Suwa, Toshihide Asou, Sumio Hoka. [Application of a PDE III inhibitor, olprinone, for fast track pediatric cardiac surgery]. Masui. The Japanese journal of anesthesiology. 2004 Mar; 53(3):258-63. doi: NULL. [PMID: 15071874]
  • Kyoko Kageyama, Toshiki Mizobe, Shinji Nozuchi, Noriko Hiramatsu, Yasufumi Nakajima, Hiroshi Aoki. Toborinone and olprinone, phosphodiesterase III inhibitors, inhibit human platelet aggregation due to the inhibition of both calcium release from intracellular stores and calcium entry. Journal of anesthesia. 2004; 18(2):107-12. doi: 10.1007/s00540-004-0228-6. [PMID: 15127258]
  • Athar Sadiq, Noriko Tamura, Minako Yoshida, Yasunari Hoshiba, Asako Kumagai, Teruhisa Tanabe, Shunnosuke Handa, Yasuo Ikeda, Shinya Goto. Possible contribution of acetylamrinone and its enhancing effects on platelet aggregation under shear stress conditions in the onset of thrombocytopenia in patients treated with amrinone. Thrombosis research. 2003; 111(6):357-61. doi: 10.1016/j.thromres.2003.09.024. [PMID: 14698653]
  • Tsukasa Nakamura, Shingo Suzuki, Chifuyu Ushiyama, Noriaki Shimada, Hikaru Koide. Effect of phosphodiesterase III inhibitor on plasma concentrations of endothelin-1 and tumour necrosis factor in patients with acute heart failure. Acta cardiologica. 2002 Feb; 57(1):19-21. doi: 10.2143/ac.57.1.2005374. [PMID: 11918129]
  • K Hirota, H Yoshioka, S Kabara, T Kudo, H Ishihara, A Matsuki. A comparison of the relaxant effects of olprinone and aminophylline on methacholine-induced bronchoconstriction in dogs. Anesthesia and analgesia. 2001 Jul; 93(1):230-3. doi: 10.1097/00000539-200107000-00046. [PMID: 11429372]
  • K Yamaura, K Akiyoshi, K Irita, T Taniyama, S Takahashi. Effects of olprinone, a new phosphodiesterase inhibitor, on gastric intramucosal acidosis and systemic inflammatory responses following hypothermic cardiopulmonary bypass. Acta anaesthesiologica Scandinavica. 2001 Apr; 45(4):427-34. doi: 10.1034/j.1399-6576.2001.045004427.x. [PMID: 11300380]
  • Y Hashimoto, K Hirota, H Yoshioka, T Kudo, H Ishihara, A Matsuki. A comparison of the spasmolytic effects of olprinone and aminophylline on serotonin-induced pulmonary hypertension and bronchoconstriction with or without beta-blockade in dogs. Anesthesia and analgesia. 2000 Dec; 91(6):1345-50. doi: 10.1097/00000539-200012000-00007. [PMID: 11093977]
  • H Amenomori, S Sasaki, K Hiraoka, Y Morimoto, S Gando, O Kemmotsu. Phosphodiesterase III inhibitor olprinone chlorate is not significantly removed by continuous venovenous hemodiafiltration. ASAIO journal (American Society for Artificial Internal Organs : 1992). 2000 Sep; 46(5):635-8. doi: 10.1097/00002480-200009000-00024. [PMID: 11016521]
  • T Arai, Y Takano, S Mizukami, I Sato. [The effect of olprinone administered after cardio-pulmonary bypass during open heart surgery, evaluated by its plasma concentrations and hemodynamic changes]. Masui. The Japanese journal of anesthesiology. 1999 Oct; 48(10):1083-90. doi: NULL. [PMID: 10554499]
  • M Kanda, S Yasuda, Y Goto, H Sumida, T Baba, T Noguchi, H Nonogi. Diuretic effect of phosphodiesterase inhibitors depends on baseline renal function in patients with congestive heart failure. The American journal of cardiology. 1999 Apr; 83(8):1274-7, A9. doi: 10.1016/s0002-9149(99)00073-9. [PMID: 10215299]
  • Y Orime, M Shiono, H Hata, S Yagi, S Tsukamoto, S Kimura, S Ohmiya, A Sezai, H Yamada, M Obana, Y Sezai. Post-operative effects of olprinone after coronary artery bypass grafting. Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia. 1998 Dec; 4(6):340-6. doi: NULL. [PMID: 9914463]
  • K Okuda, H Kudo, K Ohishi, T Kitano, H Imasaka, T Noguchi. [Effects of olprinone on IL-6 and IL-10 production during and after cardiac surgery]. Masui. The Japanese journal of anesthesiology. 1997 Dec; 46(12):1580-4. doi: NULL. [PMID: 9455080]
  • M Unoshima, H Iwasaka, S Hattori, T Kitano, T Noguchi. [Effects of loprinone hydrochloride on hemodynamics and respiratory oxygenation in patients after cardiac surgery]. Masui. The Japanese journal of anesthesiology. 1997 Aug; 46(8):1053-8. doi: NULL. [PMID: 9283160]
  • H Adachi, H Tanaka. Effects of a new cardiotonic phosphodiesterase III inhibitor, olprinone, on cardiohemodynamics and plasma hormones in conscious pigs with heart failure. Journal of cardiovascular pharmacology. 1997 Jun; 29(6):763-71. doi: 10.1097/00005344-199706000-00009. [PMID: 9234657]
  • R Murakami, K Sano, Y Murakami, T Shimada, S Morioka. Effects of intracoronary infusion of an inotropic agent, E-1020 (loprinone hydrochloride), on cardiac function: evaluation of left ventricular contractile performance using the end-systolic pressure-volume relationship. International journal of cardiology. 1995 Aug; 51(1):57-63. doi: 10.1016/0167-5273(95)02397-f. [PMID: 8522398]
  • K Tanaka, M Honda, T Kuramochi, S Morioka. Prominent inhibitory effects of tranilast on migration and proliferation of and collagen synthesis by vascular smooth muscle cells. Atherosclerosis. 1994 Jun; 107(2):179-85. doi: 10.1016/0021-9150(94)90019-1. [PMID: 7526874]
  • Y Uemura, S Tanaka, S Ida, T Yuzuriha. Pharmacokinetic study of loprinone hydrochloride, a new cardiotonic agent, in beagle dogs. The Journal of pharmacy and pharmacology. 1993 Dec; 45(12):1077-81. doi: 10.1111/j.2042-7158.1993.tb07184.x. [PMID: 7908977]
  • T Ogawa, H Ohhara, H Tsunoda, J Kuroki, T Shoji. Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 1st communication: studies on isolated guinea pig cardiac muscles. Arzneimittel-Forschung. 1989 Jan; 39(1):33-7. doi: NULL. [PMID: 2566308]
  • A C Buck. Disorders of micturition in bacterial prostatitis. Proceedings of the Royal Society of Medicine. 1975 Aug; 68(8):508-11. doi: NULL. [PMID: 681]